一种新的成像剂比外科手术后PSA水平较低的男性更早、更准确地检测出前列腺癌复发情况。 A new imaging agent detected prostate cancer recurrence earlier and more accurately than the standard in men with low PSA levels post-surgery.

清晰制药公司宣布其共同PSMA第二阶段试验达到其主要终点,显示在前列腺外科手术后,50名PSA水平较低(0.2-0.75纳克/毫升)的男子中,64台Cu-SAR-BisPSMA PET/CT检测到的PSMA阳性损伤明显高于标准68Ga-PSMA-11。 Clarity Pharmaceuticals announced its Co-PSMA Phase II trial met its primary endpoint, showing 64Cu-SAR-bisPSMA PET/CT detected significantly more PSMA-positive lesions than standard 68Ga-PSMA-11 in 50 men with low PSA levels (0.2–0.75 ng/mL) after prostate surgery. 新的成像剂查明了更多的损伤,包括小到2毫米的损伤,并在六个月前检测到复发,肿瘤对地比率较好。 The new imaging agent identified more lesions, including those as small as 2 mm, and detected recurrence up to six months earlier, with better tumor-to-background ratios. 调查结果与COBRA先前的试验结果相一致,支持64Cu-SAR-BisPSMA作为高级诊断,并辅以2个快车道指认和正在进行的登记试验。 Results align with prior COBRA trial findings and support 64Cu-SAR-bisPSMA as a superior diagnostic, backed by two Fast Track Designations and ongoing registrational trials. 将在即将举行的会议上提出完整的数据。 Full data will be presented at an upcoming conference.